The global viral vector And plasmid DNA manufacturing Market size was estimated at USD 7.19 billion in 2024 and is projected to hit around USD 46.02 billion by 2034, growing at a CAGR of 20.4% during the forecast period from 2025 to 2034.
The primary factors driving the market is the advancement in gene therapy, as the development of new gene therapies is heavily reliant on high-quality viral vectors and plasmid DNA. Furthermore, improvements in manufacturing processes have made it possible to produce viral vectors and plasmid DNA more efficiently at larger scales, while also reducing costs and improving overall quality.
Increase in investments in cell and gene therapy research space, there is exceptional demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.
Furthermore, an increase in the adoption of single-use equipment coupled with the use of suspension-based cell culture is the current industry trend. Utilizing disposable equipment improves productivity and flexibility, resulting in high final product yields. Thus, advancements in single-use technology directly impact the vector production market. Pall Corporation—one of the key companies—offers single-use equipment suitable for viral vector manufacturing. The PALL iCELLis is a single-use fixed-bed bioreactor that offers large-scale manufacturing of viral vectors in an adherent environment. Thus, an increase in the implementation of single-use technology in vector production facilities is expected to impact market growth in the coming years significantly.
The COVID-19 pandemic has created lucrative opportunities for market players by allowing them to shift their business focus toward the development of viral vectors for the SARS-CoV-2 vaccine. Viral vectors are commonly employed tools used in the discovery and development of vaccines against SARS-CoV-2. The ongoing COVID-19 pandemic has encouraged investment in this space in search of a vaccine as viral vector-based vaccines can be manufactured and designed relatively quickly with the use of same building blocks. However, viral vectors were being studied extensively by research communities well before the COVID-19 pandemic. This is because of their proven efficiency and successful application in gene and cell therapies. With the COVID-19 outbreak, applications of viral vectors were repurposed to manufacture vaccines. Although successful, viral vector manufacturing workflows face considerable challenges concerning process and scale. Thus, technology and platform developers are making significant attempts to simplify the viral vector production process.
The viral vectors and plasmid DNA manufacturing market has witnessed a significant degree of innovation in recent years. With the increasing demand for advanced gene therapy and vaccine development, manufacturers are constantly exploring new and efficient ways to produce viral vectors and plasmid DNA. One of the key innovations in this market is the use of transient transfection technology for the large-scale production of viral vectors. Another area of innovation is the use of suspension cell culture systems for viral vector production.
Large pharmaceutical and biotechnology companies are increasingly acquiring smaller vector and plasmid DNA manufacturers to access their proprietary technologies, expertise, and production capacity. This leads to consolidation within the market, giving established players greater control over pricing and market share. Smaller companies benefit from the resources and infrastructure of larger acquirers, enabling them to scale up their operations and reach a wider audience. For instance, in February 2022, Merck KGaA acquired Exelead for about USD 780 million. This would further enhance Merck’s Life Science portfolio to offer end users complete end-to-end CDMO services across the mRNA value chain.
The impact of regulations on the viral vectors and plasmid DNA manufacturing market is significant, influencing product development, manufacturing processes, and market dynamics. Compliance with regulatory standards is essential for ensuring patient safety, maintaining product quality, and gaining market access. Manufacturers need to navigate these regulatory landscapes effectively to bring innovative gene therapies to patients while meeting the stringent requirements set by regulatory agencies.
Published by Ajit Bansod
Related Reports
